Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001558370-23-007502
Filing Date
2023-05-01
Accepted
2023-05-01 16:32:38
Documents
15
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A tmb-20221231x10ka.htm   iXBRL 10-K/A 779495
2 EX-31.1 tmb-20221231xex31d1.htm EX-31.1 5939
3 EX-31.2 tmb-20221231xex31d2.htm EX-31.2 4731
  Complete submission text file 0001558370-23-007502.txt   1064539

Data Files

Seq Description Document Type Size
4 EX-101.SCH tmb-20221231.xsd EX-101.SCH 4362
5 EX-101.DEF tmb-20221231_def.xml EX-101.DEF 28997
6 EX-101.LAB tmb-20221231_lab.xml EX-101.LAB 25929
7 EX-101.PRE tmb-20221231_pre.xml EX-101.PRE 16277
9 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20221231x10ka_htm.xml XML 8121
Mailing Address 375 PHEASANT RUN NEWTOWN PA 18940
Business Address 375 PHEASANT RUN NEWTOWN PA 18940 267-759-3681
Onconova Therapeutics, Inc. (Filer) CIK: 0001130598 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36020 | Film No.: 23874253
SIC: 2834 Pharmaceutical Preparations